About the Session
From the acceleration of virtual medicine to the continued push toward value-based care, the past year has brought significant changes to the healthcare environment. The rapid implementation of these changes has largely been due to a necessity of circumstance, and hospitals and health systems are now faced with both an opportunity and challenge with the exponential growth in the volume of data and the need to harness data to understand the effectiveness of such approaches on healthcare quality and patient safety. Join Amy Abernethy, MD, PhD, Principal Deputy Commissioner of Food and Drugs and acting Chief Information Officer at the United States Food and Drug Administration, as she discusses the impact of the COVID-19 pandemic on the use of big data in healthcare and shares her thoughts on what’s next in the areas of technology and data modernization in a regulated environment. As the highest-ranking non-politically appointed official in the FDA, Dr. Abernethy will also provide insight into her leadership journey, sharing advice for leaders working to leverage real-world data and results to improve the health of their patients and communities.
This session qualifies for 1.0 ACHE Face-to-Face Education credit. Attendees must participate during the scheduled time to earn ACHE Face-to-Face Education credit.